NICM
RARE icon

Neo Ivy Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Neo Ivy Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.54M Buy
+73,601
New +$1.66M 0.41% 96
2022
Q4 		$141K Buy
+3,054
New +$120K 0.1% 245
2021
Q4 		– Sell
-3,864
Closed -$302K – 597
2021
Q3 		$302K Buy
+3,864
New +$349K 0.35% 104
2020
Q3 		– Sell
-3,864
Closed -$302K – 591
2020
Q2 		$302K Buy
+3,864
New +$256K 0.35% 104

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Neo Ivy Capital Management's RARE Position: Q1 2026 in Review

Neo Ivy Capital Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 73,601 shares worth $1.54M. The stake represents 0.41% of the portfolio and ranks #96 among its holdings. This is a return to the name: Neo Ivy Capital Management previously reported a position in RARE as recently as Q4 2022.

Neo Ivy Capital Management first reported a position in RARE in Q2 2020 and has held it in 4 quarters since. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Neo Ivy Capital Management held 73,601 shares of Ultragenyx Pharmaceutical worth $1.54M as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Neo Ivy Capital Management position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.41% of Neo Ivy Capital Management's portfolio in Q1 2026, its #96 holding.
  • Neo Ivy Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and has held it in 4 quarters since.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.